Innovent Biologics Partners with Sanegene Bio USA to Develop Hypertension Drug
China-based Innovent Biologics (HKG: 1801) has entered into a partnership with Sanegene Bio USA Inc....
Guangdong Zhongsheng Pharmaceutical’s ZSP1273 for Influenza A Accepted for Review by NMPA
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced that China’s...
Konruns Pharmaceutical Receives NMPA Go-Ahead for KC1036 Esophageal Cancer Study
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has received approval from the National Medical Products...
Jianzhijia Health-Chain to Purchase Local Drug Retailer for $23.5 Million
Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266), a Chinese healthcare company, has announced plans to...
Simcere Affiliate Shanghai Simnova Biotech Gets China Nod for CAR-T Therapy SNC109
Shanghai Simnova Biotech Co., Ltd, known as Simnova outside of China and an affiliate of...
Biocytogen and Lepu Biotechnology Develop WT1-Targeted Trispecific Antibody for Cancer Treatment
Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) and Lepu Biotechnology Co., Ltd (HKG: 2157) have...
Aidea Pharmaceutical Co. Terminates ACC006 Technology Transfer Deal with Lixin Bio
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has resolved to terminate its technology transfer agreement...
AstraZeneca to Acquire China’s Gracell Biotechnologies in $1.2 Billion Deal
Pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced its intention to fully acquire Gracell Biotechnologies...
China’s NHC Releases Third List of Recommended Generic Drugs for Development
The National Health Commission (NHC) of China has released its third list of drugs recommended...
FDA Grants Priority Review to MSD and Daiichi Sankyo’s ADC for Lung Cancer
The US Food and Drug Administration (FDA) has accepted under priority review a filing from...
AbbVie and Alpine Immune Sciences Halt Early Enrollment in Lupus Trial
AbbVie (NYSE: ABBV) and Alpine Immune Sciences (SWX: ALPN) have made the decision to prematurely...
Jiangsu Province Announces Dual Channel Management and Separate Payment Drug List
Jiangsu province’s healthcare security administration has released a list identifying drugs subject to dual channel...
J&J’s Rybrevant-Lazertinib Combo Accepted for FDA Review in NSCLC
The US Food and Drug Administration (FDA) has accepted for review Johnson & Johnson’s (J&J;...
Hunan Province Releases “Dual Channel” Drug Payment List with 226 Products
The Hunan Healthcare Security Administration has published a list of 226 drugs to be included...
Shanghai Fosun to Exclusively Commercialize Generic Entresto in China
Nanjing F&S Pharmatech Co., Ltd has officially launched its generic version of Novartis’s heart failure...
Shouyao Holdings Receives Ethical Approval for Phase III Study of ALK Inhibitor SY-3505
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received ethical...
Hengrui Pharmaceuticals-Backed Nanjing Tianyinshan Hospital Opens as Class 3A Oncology Specialist Center
Nanjing Tianyinshan Hospital, a private Class 3A oncology specialist hospital invested in by Hengrui Pharmaceuticals...
Jiangxi Jemincare Group Secures Clinical Trial Approvals for Six Drugs in China and the US
China-based Jiangxi Jemincare Group (SHA: 603222) has announced receiving clinical trial approvals for six of...
Baidu Health and Chongqing’s Fifth People’s Hospital Collaborate on Integrated Medical Services
Baidu Health has entered into a partnership with the Fifth People’s Hospital of Chongqing, a...
Suzhou Ribo Life Science Strikes Deal with Qilu Pharmaceutical for PCSK9 siRNA Drug
Suzhou Ribo Life Science Co., Ltd, a specialist in small interfering RNA (siRNA) drugs based...